← Human Trials & Peer-Reviewed Studies
Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: multicenter phase 3 double-blind randomized placebo-controlled trial (ViDiKids).
Plain-language guide to PMID 37211272 (2023): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 1682 children.
Key Facts
- PMID
- 37211272
- Journal
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Middelkoop K et al. (16 authors)
- DOI
- 10.1016/j.ijid.2023.05.010
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
Who Took Part
The abstract describes 1682 children taking part.
By PubMed's age tags, the people studied were children.
The researchers conducted a phase 3 randomized placebo-controlled trial in 1682 children attending 23 primary schools in Cape Town.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The children were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
The primary outcome was a positive end-trial QFT-Plus result, analyzed using a mixed effects logistic regression model with the school of attendance included as a random effect.
What Was Measured
PubMed files the paper under topics including South Africa, Dietary Supplements, Tuberculosis, Vitamin D, Cholecalciferol, Vitamins and Latent Tuberculosis.
The authors tagged it with the keywords Interferon-gamma release assay and Randomized controlled trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 1682 children.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases), a journal based in Canada.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.